Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Sarcoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 56pembrolizumab 50Cisplatin 43Magnetic Resonance Spectroscopy 27enfortumab vedotin 22Specimen Handling 22Nivolumab 22Cystectomy 18durvalumab 16Carboplatin 16avelumab 15Mitomycin 14atezolizumab 13Docetaxel 13Cystoscopy 12Fluorouracil 11Radiation 9Transurethral Resection of Bladder 8Radiotherapy 8Ipilimumab 8sacituzumab govitecan 7Standard of Care 7Radiosurgery 7Paclitaxel 7Immunoglobulin G 7Disulfides 7erdafitinib 6cemiplimab 6Surveys and Questionnaires 6Surgical Procedures, Operative 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Interleukin-15 × 1 year × Clear all
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡